美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · EDSA近 30 天 1 則 · 第 1 / 1 頁
- EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway
- Edesa Biotech Stock Sinks After Fresh Capital Raise
- Edesa Biotech Announces Proposed Public Offering
- Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
- EDSA: Positive Exploratory Data in Patients with AKI
- Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
- Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
- EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial
- Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
- Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
- Edesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying
- Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment
- Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
- EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality
- Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。